Meeting
2018 ASCO Annual Meeting
Lenvatinib + pembrolizumab in patients with advanced endometrial cancer: Updated results.
Authors
Vicky Makker
Memorial Sloan Kettering Cancer Center, New York, NY
Vicky Makker , Drew W. Rasco , Nicholas J. Vogelzang , Mark Messing , Marcia S. Brose , Allen Lee Cohn , Carol Aghajanian , Daniel E. Stepan , Corina E. Dutcus , Emmett V. Schmidt , Matthew Guo , Pallavi Sachdev , Robert Charles Shumaker , Matthew H. Taylor
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Other Gynecologic Cancer
Clinical Trial Registration Number
NCT02501096
Citation
J Clin Oncol 36, 2018 (suppl; abstr 5596)
DOI
10.1200/JCO.2018.36.15_suppl.5596
Abstract #
5596
Poster Bd #
323
Abstract Disclosures
Similar Posters
Poster
2019 ASCO-SITC Clinical Immuno-Oncology Symposium
A phase Ib/II trial of lenvatinib plus pembrolizumab in non-small cell lung cancer.
First Author: Marcia S. Brose
Poster
2019 ASCO-SITC Clinical Immuno-Oncology Symposium
Phase Ib/II trial of lenvatinib plus pembrolizumab in advanced melanoma.
First Author: Matthew H. Taylor
Poster
2018 ASCO Annual Meeting
A phase 1b/2 trial of lenvatinib plus pembrolizumab in patients with squamous cell carcinoma of the head and neck.
First Author: Matthew H. Taylor
Poster
2020 ASCO Virtual Scientific Program
Lenvatinib (LEN) plus pembrolizumab (PEMBRO) for early-line treatment of advanced/recurrent endometrial cancer (EC).
First Author: Vicky Makker